On Sept. 29, 2020, Moderna announced the publication of the second interim analysis of the open-label Phase 1 study of mRNA-1273, its vaccine candidate against COVID-19, in The New England Journal of Medicine. This interim analysis evaluated a two-dose vaccination schedule of mRNA-1273 given 28 days apart in 40 healthy adult participants across two dose levels (25 and 100 ﾵg) in two age cohorts (ages 56-70 and ages 71+), and reported results through Day 57 (1 month after the second dose).